Gout Treatment Retention Patterns from EHR Data, 2010-2022

2220 gout patients' urate-lowering therapy sequences were analyzed from hospital electronic health records spanning 12 years. Febuxostat was the most common first-line agent, with 90.9% maintaining therapy. The dataset, authored by Min Jung Kim and shared on figshare, examines retention rates for different treatment modification strategies.

Use Cases

• Analyze treatment retention rates based on initial agent, as described in the study results
• Compare switching versus add-on therapy patterns for gout management
• Investigate the association between comorbidities like chronic kidney disease and treatment sequence variability
• Model real-world prescription frequency and sequence patterns for urate-lowering therapies

Strengths

• Contains data from 2220 patients, providing a substantial sample size
• Based on electronic health records from two hospitals spanning 2010 to 2022
• Includes detailed subgroup analyses based on comorbidity

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect geographic or institutional bias inherent to the two hospital sources

Provenance

Source

Electronic health record data from the common data model databases of two hospitals

Collection Method

Analysis of EHR data for adults diagnosed with gout who initiated ULT and were followed for at least 2 years

Time Range

2010 to 2022

Freshness

Last updated 2026-04-17 17:33:55; freshness should be verified